Skip to main content

Table. 1 Characteristics of TDF/TDF (N = 31) and TDF/TAF groups (N = 98)

From: Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV

 

TDF/TDF groupN = 31

TDF/TAF groupN = 98

Comparisonp-value

Age (years)

50 ± 11

50 ± 12

0.79

Sex = Male

22 (71.0)

63 (64.3)

0.49

Smoking

  

0.26

 Non-smoker

16 (51.6)

51 (53.7)

 

 Ex-smoker

3 (9.7)

19 (20.0)

 

 Smoker

12 (38.7)

25 (26.3)

 

Total

31 (100.0)

95 (100.0)

 

Ethnicity

  

0.41

 Caucasian

15 (48.4)

54 (55.1)

 

 African

16 (51.6)

41 (41.8)

 

 Other

0 (0.0)

3 (3.1)

 

 Treated hypertension

5 (16.1)

25 (25.5)

0.28

 Treated dyslipidemia

4 (12.9)

11 (11.2)

0.80

 Familial cardiovascular event

1 (3.2)

4 (4.1)

0.83

 Diabetes

1 (3.2)

9 (9.2)

0.28

 

In 2016

Before switch

 

Triglycerides (mg/dL)

134 ± 82

123 ± 65

0.43

Total cholesterol (mg/dL)

184 ± 39

183 ± 38

0.90

LDL cholesterol (mg/dL)

107 ± 34

103 ± 32 (N = 97)

0.71

HDL cholesterol (mg/dL)

51 ± 12

56 ± 17 (N = 97)

0.18

Non-HDL cholesterol (mg/dL)

133 ± 39

128 ± 37 (N = 97)

0.45

Total cholesterol /HDL ratio

3.8 ± 1.2

3.6 ± 1.2 (N = 97)

0.30

Weight (kg)

74.7 ± 14.8

77.8 ± 15.9

0.34

BMI (kg/m2)

25.1 ± 4.8

26.3 ± 4.9 (N = 88)

0.24

DAD-R (%)

2.1 (0.9; 3.2) (N = 30)

1.5 (0.6; 4.0) (N = 76)

0.50

CD4 (103/mm3)

712 (509; 903)

683 (497; 928) (N = 97)

0.97

Time on TDF (years)

6 (5; 8)

6 (2; 8)

0.11